Etrasimod in the treatment of eosinophilic oesophagitis: a promising match?

Affiliations

¹ Department of gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg, 39102 Magdeburg, Germany. Electronic address: ulrike.vonarnim@med.ovgu.de.

Comment

Ulrike von Arnim. Lancet Gastroenterol Hepatol. 2025 Jul.

. 2025 Jul;10(7):606-607.

doi: 10.1016/S2468-1253(25)00125-6. Epub 2025 May 14.

¹ Department of gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg, 39102 Magdeburg, Germany. Electronic address: ulrike.vonarnim@med.ovgu.de.

No abstract available

Conflict of interest statement

UvA reports consultancy and speaker honoraria from Dr Falk Foundation, Sanofi & Regeneron, AstraZeneca, Bristol Meyer & Squibb, Eso Cap, and Pfizer.

Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial.
Dellon ES, Collins MH, Bredenoord AJ, Philpott H, Biedermann L, Dulcine M, Nguyen-Cleary T, Su C, Yu J, Tan H, Cataldi F, Wu J, Wang W, Clax P, Woolcott JC, Hirano I. Dellon ES, et al. Lancet Gastroenterol Hepatol. 2025 Jul;10(7):622-633. doi: 10.1016/S2468-1253(25)00062-7. Epub 2025 May 14. Lancet Gastroenterol Hepatol. 2025. PMID: 40381637 Clinical Trial.